Recent network pharmacology and molecular dynamics studies investigating potential melasma treatments have highlighted the involvement of estrogen receptors (ESR1 and ESR2) and the prolactin signaling pathway in melasma pathogenesis [29]. The gene discussed is ESR2; the disease is freckles.